Treatment of COVID-19 Patients With Anti-interleukin Drugs
Status:
Completed
Trial end date:
2021-04-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and effectiveness of individually or
simultaneously blocking IL-6 and IL-1 versus standard of care on blood oxygenation and
systemic cytokine release syndrome in patients with COVID-19 coronavirus infection and acute
hypoxic respiratory failure and systemic cytokine release syndrome
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Ghent
Collaborator:
Belgium Health Care Knowledge Centre
Treatments:
Antibodies, Monoclonal Interleukin 1 Receptor Antagonist Protein Siltuximab